233 related articles for article (PubMed ID: 33649535)
1. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
Liu Y; Li X; Zhang H; Zhang M; Wei Y
Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
[TBL] [Abstract][Full Text] [Related]
2. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
3. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
4. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
[TBL] [Abstract][Full Text] [Related]
5. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
6. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
7. Molecular and immune characteristics for lung adenocarcinoma patients with CMTM6 overexpression.
Wang H; Gao J; Zhang R; Li M; Peng Z; Wang H
Int Immunopharmacol; 2020 Jun; 83():106478. PubMed ID: 32278132
[TBL] [Abstract][Full Text] [Related]
8. CMTM6 shapes antitumor TÂ cell response through modulating protein expression of CD58 and PD-L1.
Miao B; Hu Z; Mezzadra R; Hoeijmakers L; Fauster A; Du S; Yang Z; Sator-Schmitt M; Engel H; Li X; Broderick C; Jin G; Gomez-Eerland R; Rozeman L; Lei X; Matsuo H; Yang C; Hofland I; Peters D; Broeks A; Laport E; Fitz A; Zhao X; Mahmoud MAA; Ma X; Sander S; Liu HK; Cui G; Gan Y; Wu W; Xiao Y; Heck AJR; Guan W; Lowe SW; Horlings HM; Wang C; Brummelkamp TR; Blank CU; Schumacher TNM; Sun C
Cancer Cell; 2023 Oct; 41(10):1817-1828.e9. PubMed ID: 37683639
[TBL] [Abstract][Full Text] [Related]
9. CMTM6 as a master regulator of PD-L1.
Yaseen MM; Abuharfeil NM; Darmani H
Cancer Immunol Immunother; 2022 Oct; 71(10):2325-2340. PubMed ID: 35294592
[TBL] [Abstract][Full Text] [Related]
10. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
[TBL] [Abstract][Full Text] [Related]
12. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
13. CMTM6 and CMTM7: New leads for PD-L1 regulation in breast cancer cells undergoing EMT.
Xiao M; Duhem C; Chammout A; Berchem G; Janji B
J Cell Biochem; 2022 Jun; 123(6):1025-1031. PubMed ID: 35575054
[TBL] [Abstract][Full Text] [Related]
14. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
15. Circular RNA hsa_circ_0067842 facilitates tumor metastasis and immune escape in breast cancer through HuR/CMTM6/PD-L1 axis.
Li J; Dong X; Kong X; Wang Y; Li Y; Tong Y; Zhao W; Duan W; Li P; Wang Y; Wang C
Biol Direct; 2023 Aug; 18(1):48. PubMed ID: 37592296
[TBL] [Abstract][Full Text] [Related]
16. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T; Yu H; Dai X; Zhang X
Front Immunol; 2022; 13():971428. PubMed ID: 35958549
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1.
Chui NN; Cheu JW; Yuen VW; Chiu DK; Goh CC; Lee D; Zhang MS; Ng IO; Wong CC
Hepatol Commun; 2022 Jan; 6(1):178-193. PubMed ID: 34558800
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
[TBL] [Abstract][Full Text] [Related]
19. Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma.
Liu LL; Zhang SW; Chao X; Wang CH; Yang X; Zhang XK; Wen YL; Yun JP; Luo RZ
Cancer Immunol Immunother; 2021 Feb; 70(2):417-429. PubMed ID: 32770259
[TBL] [Abstract][Full Text] [Related]
20. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.
Mezzadra R; Sun C; Jae LT; Gomez-Eerland R; de Vries E; Wu W; Logtenberg MEW; Slagter M; Rozeman EA; Hofland I; Broeks A; Horlings HM; Wessels LFA; Blank CU; Xiao Y; Heck AJR; Borst J; Brummelkamp TR; Schumacher TNM
Nature; 2017 Sep; 549(7670):106-110. PubMed ID: 28813410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]